Research & Literature

Atypical Chronic Myeloid Leukemia in Two Pediatric Patients.

Freedman JL, Desai AV, Bailey LC, et al.

Pediatric blood & cancer 2016; (63(1)):156-9 doi:10.1002/pbc.25694.

Activity of single-agent decitabine in atypical chronic myeloid leukemia.

Hausmann H, Bhatt VR, Yuan J, et al.

Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners 2016; (22(6)):790-794 doi:10.1177/1078155215605662.

Decitabine for the treatment of atypical chronic myeloid leukemia: A report of two cases.

Jiang H, Wu Z, Ren LI, et al.

Oncology letters 2016; (11(1)):689-692 doi:10.3892/ol.2015.3977.

How I treat atypical chronic myeloid leukemia.

Gotlib J

Blood 2017; (129(7)):838-845 doi:10.1182/blood-2016-08-693630.

Targeted next generation sequencing and identification of risk factors in World Health Organization defined atypical chronic myeloid leukemia.

Patnaik MM, Barraco D, Lasho TL, et al.

American journal of hematology 2017; (92(6)):542-548 doi:10.1002/ajh.24722.

Allogeneic stem cell transplantation in patients with atypical chronic myeloid leukaemia: a retrospective study from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation.

Onida F, de Wreede LC, van Biezen A, et al.

British journal of haematology 2017; (177(5)):759-765 doi:10.1111/bjh.14619.

SETBP1 mutations as a biomarker for myelodysplasia /myeloproliferative neoplasm overlap syndrome.

Linder K, Iragavarapu C, Liu D

Biomarker research 2017; (5()):33 doi:10.1186/s40364-017-0113-8.

Atypical chronic myeloid leukemia: a rare entity with management challenges.

Dhakal P, Gundabolu K, Amador C, et al.

Future oncology (London, England) 2018; (14(2)):177-185 doi:10.2217/fon-2017-0334.

Sudden Intracranial Hemorrhage in a Patient With Atypical Chronic Myeloid Leukemia in Chronic Phase.

Kouzuki K, Umeda K, Saida S, et al.

Journal of pediatric hematology/oncology 2018; (40(8)):e553-e556 doi:10.1097/MPH.0000000000001061.

Chronic myeloid leukemia: 2018 update on diagnosis, therapy and monitoring.

Jabbour E, Kantarjian H

American journal of hematology 2018; (93(3)):442-459 doi:10.1002/ajh.25011.

Atypical chronic myeloid leukaemia: A case of an orphan disease-A multicenter report by the Polish Adult Leukemia Group.

Drozd-Sokołowska J, Mądry K, Waszczuk-Gajda A, et al.

Hematological oncology 2018; doi:10.1002/hon.2501.

Allogeneic hematopoietic stem cell transplantation for the treatment of BCR-ABL1-negative atypical chronic myeloid leukemia and chronic neutrophil leukemia: A retrospective nationwide study in Japan.

Itonaga H, Ota S, Ikeda T, et al.

Leukemia research 2018; (75()):50-57 doi:10.1016/j.leukres.2018.11.003.

Atypical chronic myeloid leukemia achieving good response with azacitidine.

Marumo A, Mizuki T, Tanosaki S

Indian journal of cancer 2019; (56(4)):354-355 doi:10.4103/ijc.IJC_506_18.

Next-generation sequencing reveals unique combination of mutations in cis of CSF3R in atypical chronic myeloid leukemia.

Yun JW, Yoon J, Jung CW, et al.

Journal of clinical laboratory analysis 2020; (34(2)):e23064 doi:10.1002/jcla.23064.

Treatment of MDS/MPN and the MDS/MPN IWG International Trial: ABNL MARRO.

Kuykendall AT, Padron E

Current hematologic malignancy reports 2019; (14(6)):543-549 doi:10.1007/s11899-019-00553-5.

Efficacy of Ruxolitinib in Patients With Chronic Neutrophilic Leukemia and Atypical Chronic Myeloid Leukemia.

Dao KT, Gotlib J, Deininger MMN, et al.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2020; (38(10)):1006-1018 doi:10.1200/JCO.19.00895.

Distinguishing atypical chronic myeloid leukemia from other Philadelphia-negative chronic myeloproliferative neoplasms.

Sadigh S, Hasserjian RP, Hobbs G

Current opinion in hematology 2020; (27(2)):122-127 doi:10.1097/MOH.0000000000000565.

Molecular landscape and clonal architecture of adult myelodysplastic/myeloproliferative neoplasms.

Palomo L, Meggendorfer M, Hutter S, et al.

Blood 2020; (136(16)):1851-1862 doi:10.1182/blood.2019004229.

A rare atypical chronic myeloid leukemia BCR-ABL1 negative with concomitant JAK2 V617F and SETBP1 mutations: a case report and literature review.

Gao T, Yu C, Xia S, et al.

Therapeutic advances in hematology 2020; (11()):2040620720927105 doi:10.1177/2040620720927105.

Integrated Genomic, Functional, and Prognostic Characterization of Atypical Chronic Myeloid Leukemia.

Fontana D, Ramazzotti D, Aroldi A, et al.

HemaSphere 2020; (4(6)):e497 doi:10.1097/HS9.0000000000000497.

Myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes: a focused review.

Patnaik MM, Lasho T

Hematology. American Society of Hematology. Education Program 2020; (2020(1)):460-464 doi:10.1182/hematology.2020000163.

Genomics of myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes.

Patnaik MM, Lasho TL

Hematology. American Society of Hematology. Education Program 2020; (2020(1)):450-459 doi:10.1182/hematology.2020000130.

Clinicopathologic correlates and natural history of atypical chronic myeloid leukemia.

Montalban-Bravo G, Kanagal-Shamanna R, Sasaki K, et al.

Cancer 2021; (127(17)):3113-3124 doi:10.1002/cncr.33622.

Genetic Aspects of Myelodysplastic/Myeloproliferative Neoplasms.

Palomo L, Acha P, Solé F

Cancers 2021; (13(9)) doi:10.3390/cancers13092120.

Synoptic Diagnostics of Myeloproliferative Neoplasms: Morphology and Molecular Genetics.

Nann D, Fend F

Cancers 2021; (13(14)) doi:10.3390/cancers13143528.

A case of double positive myeloproliferative neoplasm: A diagnostic and therapeutic challenge.

Shaikh AB, Aribandi A, Gupta A, et al.

Indian journal of pathology & microbiology 2021; (64(4)):820-823 doi:10.4103/IJPM.IJPM_977_20.

Atypical Chronic Myeloid Leukemia: New Developments from Molecular Diagnosis to Treatment.

Castellino A, Santambrogio E, Rapezzi D, Massaia M

Medicina (Kaunas, Lithuania) 2021; (57(10)) doi:10.3390/medicina57101104.

Atypical CML with TET2 mutation, associated with NRAS and KRAS: A case report and literature review.

Abuzneid YS, Alzeerelhouseini HIA, Marzouqa N, et al.

Annals of medicine and surgery (2012) 2021; (71()):102980 doi:10.1016/j.amsu.2021.102980.

Trametinib: Could It Be a Promising Drug to Treat Atypical Chronic Myeloid Leukemia?

Elsayed M, Harry S, Nanua S, et al.

Cureus 2022; (14(7)):e26619 doi:10.7759/cureus.26619.

ETNK1 mutation occurs in a wide spectrum of myeloid neoplasms and is not specific for atypical chronic myeloid leukemia.

Shuai W, Zuo Z, Li N, et al.

Cancer 2023; (129(6)):878-889 doi:10.1002/cncr.34616.

Atypical chronic myeloid leukemia and myelodysplastic/myeloproliferative neoplasm, not otherwise specified: 2023 update on diagnosis, risk stratification, and management.

Patnaik MM, Tefferi A

American journal of hematology 2023; (98(4)):681-689 doi:10.1002/ajh.26828.

A rare case of aCML associated with CNS involvement and with aggressive clinical course.

Lame D, Pianelli M, Morsia E, et al.

Leukemia research reports 2023; (19()):100361 doi:10.1016/j.lrr.2023.100361.

Co-occurring mutations in ASXL1, SRSF2, and SETBP1 define a subset of myelodysplastic/ myeloproliferative neoplasm with neutrophilia.

Jain T, Ware AD, Dalton WB, et al.

Leukemia research 2023; (131()):107345 doi:10.1016/j.leukres.2023.107345.

Myelodysplastic Syndromes/Myeloproliferative Overlap Neoplasms and Differential Diagnosis in the WHO and ICC 2022 Era: A Focused Review.

Fontana D, Elli EM, Pagni F, Piazza R

Cancers 2023; (15(12)) doi:10.3390/cancers15123175.

CSF3R-mutant chronic myelomonocytic leukemia is a distinct clinically subset with abysmal prognosis: a case report and systematic review of the literature.

Guastafierro V, Ubezio M, Manes N, et al.

Leukemia & lymphoma 2023; (64(9)):1566-1573 doi:10.1080/10428194.2023.2227750.

Definitions, Biology, and Current Therapeutic Landscape of Myelodysplastic/Myeloproliferative Neoplasms.

Gerke MB, Christodoulou I, Karantanos T

Cancers 2023; (15(15)) doi:10.3390/cancers15153815.

Characteristics, primary treatment, and survival of MDS/MPN with neutrophilia: a population-based study.

Klein SK, Huls GA, Visser O, et al.

Blood advances 2023; (7(24)):7554-7563 doi:10.1182/bloodadvances.2023011181.

Atypical CML: diagnosis and treatment.

Breccia M

Hematology. American Society of Hematology. Education Program 2023; (2023(1)):476-482 doi:10.1182/hematology.2023000448.

Chronic neutrophilic leukemia and atypical chronic myeloid leukemia: 2024 update on diagnosis, genetics, risk stratification, and management.

Szuber N, Orazi A, Tefferi A

American journal of hematology 2024; (99(7)):1360-1387 doi:10.1002/ajh.27321.

Chronic Myelomonocytic Leukemia and Atypical Chronic Myeloid Leukemia: A National Analysis.

Vardell VA, Ose J, Rets AV, et al.

Clinical lymphoma, myeloma & leukemia 2024; (24(12)):843-851 doi:10.1016/j.clml.2024.07.013.

The spectrum of Ph-negative disease: CNL and CSF3R-related disorders.

Hasserjian RP

Hematology. American Society of Hematology. Education Program 2024; (2024(1)):270-278 doi:10.1182/hematology.2024000555.

Comprehensive analysis of Atypical chronic myeloid leukemia (aCML): Epidemiology, clinical features, and survival outcomes based on SEER database insights.

Hong Z, Wang F

Leukemia research reports 2025; (23()):100505 doi:10.1016/j.lrr.2025.100505.

Role of allo-HCT in "nonclassical" MPNs and MDS/MPNs: recommendations from the PH&G Committee and the CMWP of the EBMT.

Polverelli N, Hernández-Boluda JC, Onida F, et al.

Blood 2025; (145(22)):2561-2573 doi:10.1182/blood.2024028000.

[Allogeneic hematopoietic stem cell transplantation for the treatment of BCR::ABL-negative neutrophilic myeloid neoplasms: a clinical analysis of 12 cases].

Han TT, He Y, Liu J, et al.

Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi 2025; (46(9)):827-832 doi:10.3760/cma.j.cn121090-20241211-00560.

Atypical chronic myeloid leukemia: From diagnosis to molecular features and therapeutic options.

Iurlo A, Cattaneo D, Gianelli U, Passamonti F

HemaSphere 2025; (9(12)):e70270 doi:10.1002/hem3.70270.

Allogeneic Transplantation in the Rare Disease Myelodysplastic Syndrome/Myeloproliferative Neoplasm with Neutrophilia: Age and Disease Burden Determine Outcome.

Mohring A, Sockel K, Thiede C, et al.

Transplantation and cellular therapy 2026; (32(10)):1301.e1-1301.e10 doi:10.1016/j.jtct.2026.06.027.

Final analysis of phase 2 clinical trial of ruxolitinib and azacitidine combination therapy in patients with myelodysplastic syndrome/myeloproliferative neoplasms.

Arora S, Senapati J, Deshmukh I, et al.

Journal of hematology & oncology 2026; (19(1)).